Form 4: United Therapeutics CEO Executes Pre-Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in multiple tranches at weighted average prices ranging from $575.40 to $583.81.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The CEO retains significant beneficial ownership, including 40,513 shares held directly and substantial holdings across various family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned divestment by an executive that does not reflect a change in corporate strategy or outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive selling.
• The CEO maintains a significant long-term equity stake in the company, aligning interests with shareholders.

Negatives

• The sale represents a reduction in the CEO's direct share ownership, though it remains part of a pre-disclosed plan.

Risks

• The trading plan is scheduled to continue until December 31, 2026, or until 1,734,410 options are exercised, which may result in ongoing periodic selling pressure.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the earlier of December 31, 2026, or the exhaustion of 1,734,410 options.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive selling via 10b5-1 plans is a standard practice in the biotech industry for liquidity and tax planning, and generally does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for C-suite executives at large-cap pharmaceutical companies to avoid insider trading concerns.
• The volume of shares sold relative to the CEO's total beneficial ownership is consistent with typical executive diversification strategies.

Related Party Transactions

• The filing discloses holdings held by the reporting person's spouse and various family trusts.

Stakeholder Impact

• Minimal impact expected as the sales are pre-planned and systematic.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Martine Rothblatt, 10b5-1, Stock Options, Biotech